5 Simple Statements About ABBV-744 clinical trial phase 1 results Explained
In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Individuals will get treatment until disorder progression or the members are unable to tolerate the study drugs.Ubiquitin-associated proteins that regulate The soundness of key Tremendous enhancer-mediated proteins